RESUMEN
In many leukemia patients, a poor prognosis is attributed either to the development of chemotherapy resistance by leukemic stem cells (LSCs) or to the inefficient engraftment of transplanted hematopoietic stem/progenitor cells (HSPCs) into the bone marrow (BM). Here, we build a 3D in vitro model system of bone marrow organoids (BMOs) that recapitulate several structural and cellular components of native BM. These organoids are formed in a high-throughput manner from the aggregation of endothelial and mesenchymal cells within hydrogel microwells. Accordingly, the mesenchymal compartment shows partial maintenance of its self-renewal and multilineage potential, while endothelial cells self-organize into an interconnected vessel-like network. Intriguingly, such an endothelial compartment enhances the recruitment of HSPCs in a chemokine ligand/receptor-dependent manner, reminiscent of HSPC homing behavior in vivo. Additionally, we also model LSC migration and nesting in BMOs, thus highlighting the potential of this system as a well accessible and scalable preclinical model for candidate drug screening and patient-specific assays.
RESUMEN
Blood-contacting medical implants made of Nitinol and other titanium alloys, such as neurovascular flow diverters and peripheral stents, have the disadvantage of being highly thrombogenic. This makes the use of systemic (dual) anti-platelet/anticoagulant therapies inevitable with related risks of device thrombosis, bleeding and other complications. Meeting the urgent clinical demand for a less thrombogenic Nitinol surface, we describe here a simple treatment of standard, commercially available Nitinol that renders its surface ultra-hydrophilic and functionalized with phosphate ions. The efficacy of this treatment was assessed by comparing standard and surface-treated Nitinol disks and braids, equivalent to flow diverters. Static and dynamic (Chandler loop) blood incubation tests showed a drastic reduction of thrombus formation on treated devices. Surface chemistry and proteomic analysis indicated a key role of phosphate and calcium ions in steering blood protein adsorption and avoiding coagulation cascade activation and platelet adhesion. A good endothelialization of the surface confirmed the biocompatibility of the treated surface. STATEMENT OF SIGNIFICANCE: Titanium alloys such as Nitinol are biocompatible and show favorable mechanical properties, which led to their widespread use in medical implants. However, in contact with blood their surface triggers the activation of the intrinsic coagulation cascade, which may result in catastrophic thrombotic events. The presented results showed that a phosphate functionalization of the titanium oxide surface suppresses the activation of both coagulation cascade and platelets, avoiding the subsequent formation of a blood clot. This novel approach has therefore a great potential for mitigating the risks associated to either thrombosis or bleeding complications (due to systemic anticoagulation) in patients with cardiovascular implants.
Asunto(s)
Aleaciones , Proteómica , Adsorción , Aleaciones/farmacología , Humanos , Stents , Propiedades de SuperficieRESUMEN
The loss of fetal membrane (FM) integrity and function at an early time point during pregnancy can have devastating consequences for the fetus and the newborn. However, biomaterials for preventive sealing and healing of FMs are currently non-existing, which can be partly attributed to the current fragmentary knowledge of FM biology. Despite recent advances in proteomics analysis, a robust and comprehensive description of the amnion proteome is currently lacking. Here, by an optimized protein sample preparation and offline fractionation before liquid chromatography coupled to mass spectrometry (LC-MS) analysis, we present a characterization of the healthy human term amnion proteome, which covers more than 40% of the previously reported transcripts in similar RNA sequencing datasets and, with more than 5000 identifications, greatly outnumbers previous reports. Together, beyond providing a basis for the study of compromised and preterm ruptured FMs, this comprehensive human amnion proteome is a stepping-stone for the development of novel healing-inducing biomaterials. The proteomic dataset has been deposited in the ProteomeXchange Consortium with the identifier PXD019410.
RESUMEN
BACKGROUND: Undescended (cryptorchid) testes in patients with defective mini-puberty and low testosterone levels contain gonocytes that fail to differentiate normally, which impairs the development of Ad spermatogonia and ultimately leads to adult infertility. Treatment with the gonadotropin-releasing hormone agonist GnRHa increases luteinizing hormone and testosterone and rescues fertility in the majority of pathological cryptorchid testes. Several Y-chromosomal genes in the male-specific Y region (MSY) are essential for spermatogenesis, testis development and function, and are associated with azoospermia, infertility and cryptorchidism. In this study, we analyzed the expression of MSY genes in testes with Ad spermatogonia (low infertility risk patients) as compared to testes lacking Ad spermatogonia (high infertility risk) before and after curative GnRHa treatment, and in correlation to their location on the Y-chromosome. RESULTS: Twenty genes that are up- or down-regulated in the Ad- group are in the X-degenerate or the ampliconic region, respectively. GnRHa treatment increases mRNA levels of 14 genes in the ampliconic region and decreases mRNA levels of 10 genes in the X-degenerate region. CONCLUSION: Our findings implicate Y-chromosomal genes, including USP9Y, UTY, TXLNGY, RBMY1B, RBMY1E, RBMY1J and TSPY4, some of which are known to be important for spermatogenesis, in the curative hormonal treatment of cryptorchidism-induced infertility.
CONTEXTE: La non descente des testicules chez les garçons cryptorchides qui présentent une mini-puberté défectueuse et un taux réduit de testostérone (T) ont des gonocytes incapables de se différencier normalement en spermatogonie Ad. Cette dernière entraîne une infertilité. Le traitement avec l'agoniste du GnRH (GnRHa) augmente les taux de LH et T et permet de sauvegarder la fertilité chez la majorité des testicules cryptorchides pathologiques. Plusieurs gènes du chromosome Y localisés dans la région spécifique du mâle (MSY) sont essentiels pour la spermatogénèse, ainsi que pour le développement et la fonction testiculaires, et sont associés à l'azoospermie, l'infertilité et la cryptorchidie. Dans cette étude, nous avons analysé l'expression des gènes dans la région MSY des testicules avec et sans spermatogonies Ad, avant et après traitement par GnRHa. Les résultats sont corrélés avec la localisation des gènes dans le chromosome Y. RÉSULTATS: Dans le groupe Ad-, vingte gènes dont l'expression est. régulée à la hausse ou à la baisse sont respectivement localisés dans la région dégénérée du X ou dans la région ampliconique. Le traitement par GnRHa augmente les taux de mRNA de 14 gènes dans la région ampliconique et réduit l'expression de 10 gènes dans la région dégénérée du X. CONCLUSION: Nos résultats impliquent une participation des gènes du chromosome Y, compris USP9Y, UTY, TXLNGY, RBMY1B, RBMY1E, RBMY1J et TSPY4, dont certains sont importants pour la fertilité, dans le traitement curatif de l'infertilité due à la cryptorchidie.
RESUMEN
BACKGROUND: Follicle stimulating hormone and testosterone stimulate Sertoli cells to support germ cell function and differentiation. During mini-puberty, when gonadotropin (GnRH) stimulates increases in plasma luteinizing hormone (LH) and testosterone levels, gonocytes are transformed into Ad spermatogonia. In cryptorchidism, impaired gonadotropin secretion during mini-puberty results in insufficient LH and testosterone secretion, impaired gonocyte transition to Ad spermatogonia, and perturbed Sertoli cell proliferation. Treatment with a gonadotropin-releasing hormone agonist (GnRHa/Buserelin) induced gonocytes to differentiate into Ad spermatogonia and rescued fertility. The present study evaluated the impact of low LH secretion on Sertoli cell function by comparing differential gene expression data between testes with low LH that lacked Ad spermatogonia (Ad-) and testes that completed mini-puberty (Ad+). Furthermore, we analyzed changes in the transcription of selected Sertoli cell specific genes in response to GnRHa treatment. RESULTS: Ad- testes showed reduced expression of nine out of 40 selected Sertoli cell specific genes compared to Ad+ testes. GnRHa treatment repressed most of the Sertoli cell specific genes, including the inhibins, but it increased the expression of genes that regulate apoptosis (FASLG) and proliferation (GDNF). CONCLUSIONS: Impaired-minipuberty with decreased LH and testosterone levels affected Ad and Sertoli cell development through positive and negative regulation of morphoregulatory and apoptotic genes. GnRHa treatment had a repressive effect on most Sertoli cell specific genes, which suggested that Sertoli cells underwent a cellular rearrangement. We propose that gonadotropin-dependent increases in FASLG and GDNF expression drove Sertoli cell proliferation and germ cell self-renewal and supported the transition of gonocytes to Ad spermatogonia, independent of inhibins.
CONTEXTE: L'hormone folliculostimulante et la testostérone stimulent les cellules de Sertoli pour soutenir la fonction et la différentiation des cellules germinales. Pendant la minipuberté, lorsque la gonadotrophine (GnRH) stimule les augmentations des taux plasmatiques d'hormone lutéinisante (LH) et de testostérone, les gonocytes sont transformés en spermatogonies Ad. Dans la cryptorchidie, une sécrétion altérée de gonadotrophine lors de la minipuberté entraine une sécrétion insuffisante de LH et de testostérone, une altération de la transition des gonocytes en spermatogonies Ad, et une perturbation de la prolifération des cellules de Sertoli. Un traitement par agoniste de la gonadolibérine (GnRHa/Buserelin) induit une différenciation des gonocytes en spermatogonies Ad et sauvegarde la fertilité.Cette étude a évalué l'impact d'un taux de LH bas sur la fonction des cellules de Sertoli en comparant les données d'expression différentielle de gènes entre des testicules avec LH basse qui sont dépourvus de spermatogonies Ad (Ad-) et des testicules qui ont fini la minipuberté (Ad+). En outre, la réponse au traitement par GnRHa a été analysée par les modifications de la transcription de gènes sélectionnés pour être spécifiques de la cellule de Sertoli. RÉSULTATS: Les testicules Ad- présentent une expression réduite de 9 des 40 gènes sélectionnés pour être spécifiques de la cellule de Sertoli par comparaison aux testicules Ad+. Le traitement par GnRHa a réprimé l'expression de la plupart des gènes spécifiques de la cellule de Sertoli, y compris les inhibines, mais a augmenté l'expression de gènes qui régulent l'apoptose (FASLG) et la prolifération (GDNF). CONCLUSIONS: Une minipuberté altérée par des taux diminués de LH et de testostérone affecte le développement des spermatogonies Ad et des cellules de Sertoli par une régulation positive et négative de gènes morphorégulateurs et apoptotiques. Le traitement par GnRHa a un effet inhibiteur sur la plupart des gènes spécifiques de la cellule de Sertoli, ce qui suggère que les cellules de Sertoli subissent un réarrangement cellulaire. Nous proposons que les augmentations gonadotrophine-dépendantes de l'expression de FASLG et de GDNF dirigent la prolifération des cellules de Sertoli et l'auto-renouvèlement des cellules germinales, et qu'elles sont le support de la transition gonocytes vers spermatogonies Ad, indépendante des inhibines.
RESUMEN
Defective mini-puberty results in insufficient testosterone secretion that impairs the differentiation of gonocytes into dark-type (Ad) spermatogonia. The differentiation of gonocytes into Ad spermatogonia can be induced by administration of the gonadotropin-releasing hormone agonist, GnRHa (Buserelin, INN)). Nothing is known about the mechanism that underlies successful GnRHa treatment in the germ cells. Using RNA-sequencing of testicular biopsies, we recently examined RNA profiles of testes with and without GnRHa treatment. Here, we focused on the expression patterns of known gene markers for gonocytes and spermatogonia, and found that DMRTC2, PAX7, BRACHYURY/T, and TERT were associated with defective mini-puberty and were responsive to GnRHa. These results indicate novel testosterone-dependent genes and provide valuable insight into the transcriptional response to both defective mini-puberty and curative GnRHa treatment, which prevents infertility in man with one or both undescended (cryptorchid) testes.
RESUMEN
It has been known for many years that boys with unilateral or bilateral undescended testis (cryptorchidism) tend to have a low IQ, and those who belong to the high infertility risk (HIR) group perform less well at school than low infertility risk (LIR) patients. However, the molecular biological processes underlying this phenomenon are not understood. In this study, we report the outcome of testicular RNA profiling for genes involved in long-term memory formation. We analyzed the histology and the transcriptome of testicular biopsies from bilateral HIR cryptorchid boys, comparing those who received GnRHa treatment for 6 months after the first surgery with those who did not receive GnRHa before the second surgery. We found that GnRHa treatment alters the testicular mRNA levels of neuronal genes that are involved in long-term memory and testosterone synthesis. These data highlight a possible molecular link between cryptorchidism, impaired mini-puberty, and diminished cognitive functions. Our results are consistent with the hypothesis that hypogonadotropic hypogonadism in cryptorchid boys with altered mini-puberty may affect neuronal genes important for memory and learning, which could help explaining the negative correlation between cryptorchidism and intellectual abilities.
Asunto(s)
Criptorquidismo/tratamiento farmacológico , Criptorquidismo/genética , Hormona Liberadora de Gonadotropina/análogos & derivados , Memoria a Largo Plazo/efectos de los fármacos , Testículo/metabolismo , Preescolar , Regulación de la Expresión Génica/efectos de los fármacos , Hormona Liberadora de Gonadotropina/farmacología , Hormona Liberadora de Gonadotropina/uso terapéutico , Humanos , Lactante , Infertilidad Masculina/genética , Masculino , ARN Mensajero/genética , ARN Mensajero/metabolismo , Análisis de Secuencia de ARN , Testículo/efectos de los fármacosRESUMEN
The gonadotropin-releasing hormone agonist (GnRHa; Buserelin) rescues fertility during adulthood in the majority of high infertility risk cryptorchid boys presenting with defective mini-puberty. However, the molecular events governing this effect are not understood. We report the outcome of an RNA profiling analysis of testicular biopsies from 4 operated patients who were treated with GnRHa for 6 months versus 3 operated controls who were not treated. GnRHa induces a significant transcriptional response, including protein-coding genes involved in pituitary development, the hypothalamic-pituitary-gonadal axis, and testosterone synthesis. Furthermore, we observed an increased abundance of long noncoding RNAs (lncRNAs) participating in epigenetic processes, including AIRN, FENDRR, XIST, and HOTAIR. These data are consistent with the hypothesis that hypogonadotropic hypogonadism in boys with altered mini-puberty is the consequence of a profoundly altered gene expression program involving protein-coding genes and lncRNAs. Our results point to molecular mechanisms that underlie the ability of GnRHa to rescue fertility.
Asunto(s)
Criptorquidismo/tratamiento farmacológico , Criptorquidismo/genética , Fertilidad/genética , Hormona Liberadora de Gonadotropina/uso terapéutico , Sistema Hipotálamo-Hipofisario/patología , Testosterona/metabolismo , Preescolar , Criptorquidismo/cirugía , Fertilidad/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Hormona Liberadora de Gonadotropina/farmacología , Humanos , Lactante , Masculino , Hipófisis/efectos de los fármacos , Hipófisis/crecimiento & desarrollo , Mapas de Interacción de Proteínas/efectos de los fármacos , ARN Largo no Codificante/genética , ARN Largo no Codificante/metabolismo , Testosterona/biosíntesisRESUMEN
The whole genome RNA profiling of testicular biopsies by DNA strand-specific RNA sequencing was examined to determine a potential causative role of isolated congenital cryptorchidism in azoospermia and/or infertility in the context of our previously published GeneChip data. Cryptorchid patients, aged 7 months to 5 years and otherwise healthy, were enrolled in this prospective study. During surgery, testicular tissue biopsies were obtained for histological examination and RNA sequencing. Fifteen patients were selected based on the histological results and were divided into 2 groups. Seven were classified as belonging to the high infertility risk (HIR) and 8 to the low infertility risk (LIR) group. Cryptorchid boys in the HIR group lacked transformation of gonocytes into Ad spermatogonia due to impaired mini-puberty. This group of patients will be infertile despite successful surgery. The new important finding was a decreased PROK2, CHD7, FGFR1, and SPRY4 gene expression in the HIR group. Furthermore, identification of multiple differences in gene expression between HIR and LIR groups underscores the importance of an intact hypothalamic-pituitary-gonadal axis for fertility development. Our RNA profiling data strongly support the theory that in the HIR group of cryptorchid boys insufficient PROK2/CHD7/FGFR1/SPRY4 gene expression induces deficient LH secretion, resulting in impaired mini-puberty and infertility. We therefore recommend hormonal treatment for this cohort of cryptorchid boys with defective mini-puberty following a seemingly successful orchidopexy.
Asunto(s)
Criptorquidismo/metabolismo , Hipogonadismo/metabolismo , Hipogonadismo/fisiopatología , Pubertad/fisiología , Azoospermia/genética , Azoospermia/metabolismo , Azoospermia/fisiopatología , Preescolar , Criptorquidismo/genética , Criptorquidismo/fisiopatología , ADN Helicasas/genética , ADN Helicasas/metabolismo , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Hormonas Gastrointestinales/genética , Hormonas Gastrointestinales/metabolismo , Humanos , Hipogonadismo/genética , Lactante , Infertilidad Masculina/genética , Infertilidad Masculina/metabolismo , Péptidos y Proteínas de Señalización Intracelular/genética , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Masculino , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/metabolismo , Neuropéptidos/genética , Neuropéptidos/metabolismo , Estudios Prospectivos , Pubertad/genética , Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos/genética , Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos/metabolismo , Espermatogonias/metabolismo , Espermatogonias/fisiologíaRESUMEN
We present a strategy to obtain milligrams of highly post-translationally modified eukaryotic proteins, transiently expressed in mammalian cells as rigid or cleavable fusions with a mammalianized version of bacterial maltose-binding protein (mMBP). This variant was engineered to combine mutations that enhance MBP solubility and affinity purification, as well as provide crystal-packing interactions for increased crystallizability. Using this cell type-independent approach, we could increase the expression of secreted and intracellular human proteins up to 200-fold. By molecular replacement with MBP, we readily determined five novel high-resolution structures of rigid fusions of targets that otherwise defied crystallization.